Cognitive impairment in hypertension
| Autor: | Yu. A. Starchina, Vladimir Vladimirovich Zakharov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
hypertension Population Perfusion scanning 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Neuroprotective Drugs Internal medicine medicine Dementia Risk factor education Cognitive impairment RC346-429 Stroke antihypertensive therapy cerebral microangiopathy cognitive impairment education.field_of_study business.industry Memantine medicine.disease Psychiatry and Mental health Clinical Psychology Cardiology Neurology (clinical) Neurology. Diseases of the nervous system business 030217 neurology & neurosurgery medicine.drug dementia |
| Zdroj: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika, Vol 13, Iss 1, Pp 113-118 (2021) |
| ISSN: | 2310-1342 2074-2711 |
| Popis: | As the life expectancy of the population increases, cognitive impairment (CI) caused by cerebrovascular diseases is becoming an increasingly urgent problem. The leading role of hypertension in the development of CI of various origins has led to intense discussions about blood pressure control as a potential therapeutic strategy for achieving optimal brain perfusion and about the prevention of mild and moderate CI. Hypertension is the main modifiable risk factor for stroke and cerebral small vessel damage that results in nonstroke-related CI. Antihypertensive therapy plays an essential role in preventing the development and slowing down the progression of CI through blood pressure control. Neurometabolic and neuroprotective drugs (Vinpotropil ® , Cholitilin ® ) are actively used to treat CI that does not reach the degree of dementia. When dementia develops, reversible NMDA receptor inhibitors (memantine) and central acetylcholinesterase inhibitors are used to correct CI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|